Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. [electronic resource]
- Urology Aug 2007
- 396-401 p. digital
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
1527-9995
10.1016/j.urology.2007.03.052 doi
Antineoplastic Combined Chemotherapy Protocols--therapeutic use Depsipeptides--administration & dosage Docetaxel Humans Male Prostatic Neoplasms--drug therapy Taxoids--administration & dosage Tumor Cells, Cultured